Full-Time

Maintenance Specialist

Kyowa Kirin

Kyowa Kirin

1,001-5,000 employees

Global specialty pharma focused on antibodies

Compensation Overview

$25 - $35/hr

+ Annual Bonus Program + 401(k) company match + Long-Term Incentive Program

Sanford, NC, USA

In Person

Requires up to 5% domestic travel.

Bachelor's

Category
Facilities Operations (1)
Required Skills
SAP Products

Get referred to Kyowa Kirin

See people who can refer or advise you

Requirements
  • A high school diploma or equivalent is required.
  • Two to four years of experience working within a computerized maintenance management system environment is required, with preference for SAP or Microsoft Dynamics experience.
  • Two to four years of relevant experience with a computerized maintenance management system, engineering document management system, authoring and supporting deviations, and change controls is required.
  • Experience with computerized maintenance management system platforms such as D365 EAM, SAP PM, Maximo, or other computerized maintenance management system platforms is preferred.
  • Experience with an engineering document management system, preferably Adept, is preferred.
  • Ability to work collaboratively with clients to promote excellence in customer service.
  • Ability to import data, create templates, and export data as required is a plus.
  • Ability to generate reports and modify reports as needed.
  • Strong communication and organizational skills.
  • Excellent attention to detail and data integrity.
  • Ability to navigate ambiguity, set clear outcomes, track progress, follow through on commitments, and ensure actions lead to measurable organizational results.
  • Ability to adapt to change, guide teams through evolving challenges, and work effectively in a global environment.
  • Ability to communicate thoughtfully, actively listen, consider others' perspectives, and manage relationships respectfully.
  • Ability to promote inclusive collaboration, contribute positively to the work environment, and work resourcefully and proactively.
  • Ability to apply an enterprise-wide mindset and deliver cohesive, integrated solutions.
  • Ability to work on-site in a construction environment and ultimately at a biotech manufacturing site, with exposure to machinery, noise, and physical hazards while using proper personal protective equipment.
  • Ability to travel domestically up to 5%.
Responsibilities
  • Administer and maintain the computerized maintenance management system to support preventive, corrective, and predictive maintenance programs.
  • Administer and maintain the engineering document management system to control and maintain custody of documents related to buildings and equipment.
  • Develop, update, and manage asset records, preventive-maintenance schedules, work orders, and maintenance history in the computerized maintenance management system.
  • Work with information technology and computerized maintenance management system and engineering document management system vendors to troubleshoot technical issues and implement improvements.
  • Generate periodic reports and key performance indicators related to maintenance performance, equipment reliability, and compliance.
  • Schedule calibrations, maintenance, and vendor preventive-maintenance activities.
  • Maintain data integrity for new assets, asset moves, and asset retirements.
  • Provide software training to end users and new administrators and serve as a liaison for problem-solving and escalation.
  • Lead or participate in system upgrades, validation, and configuration changes while ensuring compliance with 21 CFR Part 11 and other relevant regulations.
  • Author and support deviations, change controls, and corrective and preventive actions for the maintenance department.
  • Support regulatory audits by providing documentation, maintenance history reports, and computerized maintenance management system and engineering document management system data as needed.
Desired Qualifications
  • Associate or bachelor's degree.
  • Preference for experience with SAP or Microsoft Dynamics.
  • Experience with computerized maintenance management system platforms such as D365 EAM, SAP PM, Maximo, or other computerized maintenance management system platforms.
  • Experience with an engineering document management system, preferably Adept.
  • Ability to import data, create templates, and export data as required.

1) What does this company do? Kyowa Kirin develops specialty pharmaceutical drugs with a focus on nephrology, oncology, and immunology, built on a foundation of fermentation technology and antibody science. 2) How does this company's product(s) work? It uses fermentation-derived biology and antibody-based approaches to create therapies that target kidney disease, cancer, and immune-related conditions, delivered as approved medicines after research, development, and clinical testing. 3) How is this company different from its competitors? It blends deep fermentation and microbiology expertise with antibody technology from its history, plus a global specialty-drug focus, resulting from a merger of Kyowa Hakko Kogyo and Kirin Pharma that combined fermentation know-how with pharmaceutical resources. 4) What is this company's goal? To develop and commercialize innovative treatments that address unmet medical needs in nephrology, oncology, and immunology on a global scale.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1885

Get referred to Kyowa Kirin

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA selected Sanford for PreCheck on June 30, 2026, accelerating biologics launch readiness.
  • Crysvita expanded adult XLH dosing in May 2026, extending treatment uptake and persistence.
  • 2025 revenue reached ¥496.8 billion, and 2026 guidance rises to ¥520.0 billion.

What critics are saying

  • Crysvita sales still dominate; any reimbursement squeeze or safety issue hits 2026 results fast.
  • Sanford slips past 2027, and the FDA PreCheck advantage evaporates into delay and cost.
  • March 2026 leadership turnover, including CFO Motohiko Kawaguchi, disrupts execution and accountability.

What makes Kyowa Kirin unique

  • Crysvita remains the only approved XLH therapy, protecting a rare-disease franchise in 2026.
  • Sanford, North Carolina gives Kyowa Kirin a first U.S. biologics manufacturing base by 2027.
  • Benchling deployment in Tokyo and Fuji formalizes AI-enabled R&D workflows across discovery.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Paid Vacation

Paid Sick Leave

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Unlimited Paid Time Off

Hybrid Work Options

Pet Insurance

Tuition Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

-2%
Yahoo Finance
Aug 26th, 2026
Cognizant wins Kyowa Kirin AI R&D deal to implement Benchling platform in Japan

Cognizant Technology Solutions will support Kyowa Kirin in implementing Benchling, an AI-driven R&D platform, at the Tokyo and Fuji Research Parks in Japan. The engagement includes platform setup, data migration, ongoing maintenance, and workflow optimization for drug discovery research. The deal reinforces Cognizant's enterprise-scale AI automation capabilities in life sciences digitalization. However, it is unlikely to shift near-term catalysts around broader AI adoption or risks that AI may erode demand for labour-intensive services. Cognizant's narrative projects $24.9 billion revenue and $3.1 billion earnings by 2029, requiring 5.2% yearly revenue growth. The most optimistic analysts forecast revenue reaching $26.1 billion and earnings of $3.9 billion by 2029, depending on how AI investments translate into higher-margin work.

IT Business Today
Aug 17th, 2026
Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation.

Kyowa Kirin modernizes with Cognizant and Benchling R&D with AI and automation. Last updated: August 17, 2026 12:53 pm Kyowa Kirin has chosen Cognizant and Benchling to support the rollout of Benchling's cloud-based R&D platform at its Tokyo Research Park and Fuji Research Park. The platform brings experimental planning, data collection, AI tools, and workflow automation into one place. Researchers can connect experimental equipment directly to Benchling, allowing data to be captured as structured and searchable records instead of being entered manually. That matters as Kyowa Kirin's research work becomes more complex and its pipeline expands. The company expects the platform to help speed up activities ranging from identifying drug targets to selecting new drug candidates. Researchers will also be able to search past experiments, generate reports, examine relationships between studies, and support molecular design using the platform's analytical and AI capabilities. Cognizant will handle the implementation using Benchling, including platform setup, data migration, deployment, and the ongoing upkeep too. This partnership shows where pharma research and development is headed, more or less, these days. More of the work around data handling and routine processes is being moved into connected digital systems, while AI is being brought closer to the research itself rather than treated as a separate tool. ITBT Staffwriter is an in-house contributor at IT Business Today, responsible for delivering timely News and QuickBytes. The author covers the latest developments across IT, tech, and enterprise solutions to keep readers informed with concise and impactful updates. August 17, 2026

Benzinga
Dec 15th, 2025
Link Cell Therapies raises $92M to advance CAR-T cancer treatments for solid and liquid tumors

Link Cell Therapies has emerged from stealth with $60 million in Series A funding led by Johnson & Johnson Innovation – JJDC, bringing total capital raised to $92 million. The South San Francisco–based oncology company is developing CAR-T therapies for solid and liquid tumours using proprietary logic-gating technology. The platform enables safe targeting of multiple antigens co-expressed on cancer cells whilst sparing healthy tissue. Co-founded by Dr Robbie Majzner and Dr Crystal Mackall at Stanford University in 2022, Link's lead programme, LNK001 for renal cell carcinoma, is on track for an IND application and Phase I trial in 2026. The Series A round included participation from founding investors Samsara BioCapital and Sheatree Capital, alongside new backers Bristol Myers Squibb, Kyowa Kirin and Wing Venture Capital.

FinSMEs
Mar 4th, 2025
Garuda Therapeutics Closes $50M Series A-1 Financing

Garuda Therapeutics, a Cambridge, MA-based hematopoietic stem cell (HSC) therapies company, raised $50M in Series A-1 funding

Cimeio Therapeutics
Dec 10th, 2024
Cimeio Therapeutics Announces Partnership with Kyowa Kirin to Develop Novel Cell Therapies

The partnership combines Cimeio's proprietary Shielded Cell and Immunotherapy (SCIP) platform with Kyowa Kirin's expertise in cellular therapies and underscores both companies' commitment to using emerging cell and gene therapy technologies to develop new ways to treat patients.